Glyburide

ABSTRACT: The aim of the present study is to design and evaluate the controlled release Glyburide trilayer matrix tablets, to achieve zero-order drug release for sustained plasma concentration. Matrix tablets were prepared by direct compression whereas three-layer tablets were prepared by compressing polymer barrier layers on both sides of the core containing the drug. Formulations were prepared by using different grades of hydroxy propyl methyl cellulose and Ethyl cellulose. Based on the evaluation parameters, drug dissolution profile and release drug kinetics HF16 was found to be optimized formulation. These results also demonstrated the suitability of three-layered tablet formulation of Glyburide to provide controlled release for prolonged period and improved linearity for Glyburide in comparison to marketed product in the management of Diabetes. Keywords: Glyburide, Type II Diabetes, HPMC Grades, EC, MCC, Release order kinetics.  

Drug Interactions have become very common now-a-days. In drug interactions there are mainly three types in that the most important interactions are drug-drug interactions. By keeping in mind about these interactions we have done research by taking Diabetes as the main disease and if same person is suffering any other disease like we have chosen Hypertension. Our main aim is to find out the Interactions between Glyburide and Amlodipine and another scenario is little different with another class of drug that is Enalapril and with Sulphonyl urea derivative drug that is Glyburide. We found that the Glyburide have shown the 49.9% of inhibition. The Amlodipine and Enalapril groups showed 28.9% and 33.7% inhibition rates against the Glyburide group. The combined groups Glyburide with Amlodipine and Glyburide with Enalapril have shown 39% and 43.3% inhibition rates. More results can be obtained if we have done Pharmacokinetic study.